The PKM Knockout A549 Cell Line is a CRISPR/Cas9-edited knockout cell line originating from the human A549 lung adenocarcinoma cell line, engineered to carry a targeted disruption of the PKM gene. This cell line provides a stable, loss?of?function model for dissecting the contributions of pyruvate kinase to cancer cell metabolism, signal transduction, and gene expression. By employing CRISPR/Cas9-mediated gene disruption, the model circumvents compensatory adaptation often observed with transient suppression, delivering a consistent genetic background for rigorous experimental interrogation.
The parental A549 cell line is an epithelial cell line derived from the tumor tissue of a patient with lung adenocarcinoma. It represents a widely utilized model system for non?small cell lung cancer (NSCLC), retaining key oncogenic driver mutations (including mutant KRAS) and displaying high glycolytic activity characteristic of the Warburg effect. A549 cells are amenable to genetic manipulation and have been extensively employed in studies of tumor metabolism, drug sensitivity, and in vivo xenograft growth, making them a relevant platform for investigating PKM function.
PKM encodes the glycolytic enzyme pyruvate kinase, which catalyzes the transfer of a phosphate group from phosphoenolpyruvate to ADP, generating pyruvate and ATP. The PKM2 isoform, predominantly expressed in proliferating cells and tumors, also possesses non?metabolic roles as a transcriptional coactivator. PKM2 is regulated by growth factor?activated pathways: signaling downstream of EGF and PDGF via PI3K/AKT/mTOR promotes PKM2 expression and modulates its enzymatic activity. Transcription factors HIF1A and MYC directly upregulate PKM expression under hypoxic and mitogenic conditions. PKM2 interacts directly with HIF1A and STAT3, enhancing the transcription of glycolytic targets (GLUT1, LDHA) and HIF1A? or STAT3?dependent genes, thereby coordinating metabolic rewiring with cell proliferation and survival programs. Key downstream metabolites include pyruvate, lactate, and ATP, and the reaction helps maintain cellular NAD+ pools.
In the A549 context, where oncogenic KRAS and EGFR signaling drive a highly glycolytic phenotype, PKM knockout profoundly disrupts metabolic homeostasis. Loss of PKM activity impairs the final step of glycolysis, reducing pyruvate and ATP production and limiting the supply of glycolytic intermediates for the pentose phosphate pathway and nucleotide biosynthesis. This metabolic collapse curtails the Warburg effect, diminishes proliferative capacity, and sensitizes cells to apoptosis. Consequently, the PKM Knockout A549 Cell Line serves as a powerful tool for elucidating PKM??s dual metabolic and transcriptional functions and for validating the dependency of NSCLC on PKM2-driven anabolic metabolism.
Researchers can employ this knockout line in a broad spectrum of applications including cancer metabolism studies, drug target validation, and analysis of the Warburg effect. Representative assays include extracellular acidification rate (ECAR) measurement to assess glycolytic flux, lactate production assays, glucose uptake quantification, and pyruvate kinase activity assays. The line is also suited for proliferation, apoptosis, and clonogenic survival assays, as well as for transcriptomic (RNA?seq, RT?qPCR) and metabolomic profiling. In vivo, xenograft tumor growth studies can directly evaluate the impact of PKM loss on tumorigenicity. For further technical details or to discuss custom cell engineering services, please contact Ascent Research.
